AI and Cancer Research (Top Journals) ── Prostate ── 2026-09-30

New papers on cancer and AI from 26 medical, oncology and general journals with an impact factor of 10 or more, collected from the journals' own websites and selected by Jev (an AI that makes language judgements): is it original research, is AI central, which of six themes, and does it concern treatment or trials. Summaries are written from each abstract only and make no claim about efficacy or safety.

Prostate cancer: treatment, trials and AI

• A novel multiomics machine learning signature identifies rapid progression in clinically low risk prostate cancer.
  NPJ digital medicine · 2026-09-14 · Evidence: retrospective computational analysis of existing cohorts with external validation of associations

  A network-based machine learning framework integrating somatic copy-number, epigenomic and transcriptomic data in TCGA-PRAD (n=498) identified ZNF268, whose promoter hypermethylation marked a transition confined to low/intermediate-risk disease. A Rewiring Score from co-expression network changes was associated with progression-free survival (HR 2.79) and with biochemical recurrence in two external cohorts. Drug-sensitivity results are computational predictions.

• Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer☆
  Annals of Oncology · 2026-06-05 · Evidence: biomarker analysis within randomized phase III trials (no results stated in the provided abstract)

  This study evaluated a digital pathology multimodal artificial intelligence model, previously validated as a prognostic biomarker, for prediction of abiraterone benefit in nonmetastatic clinically very high-risk prostate cancer, using two STAMPEDE phase III trials. The abstract provided states only the rationale and objective; no results are reported in it.

← Back to this issue